



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Abu-Bonsrah, KD;Zhang, D;Newgreen, DF

Title:

CRISPR/Cas9 Targets Chicken Embryonic Somatic Cells in Vitro and in Vivo and generates Phenotypic Abnormalities

Date:

2016-10-03

Citation:

Abu-Bonsrah, K. D., Zhang, D. & Newgreen, D. F. (2016). CRISPR/Cas9 Targets Chicken Embryonic Somatic Cells in Vitro and in Vivo and generates Phenotypic Abnormalities. *Scientific Reports*, 6 (1), <https://doi.org/10.1038/srep34524>.

Persistent Link:

<https://hdl.handle.net/11343/260429>

License:

CC BY

SCIENTIFIC REPORTS



OPEN

CRISPR/Cas9 Targets Chicken Embryonic Somatic Cells *In Vitro* and *In Vivo* and generates Phenotypic Abnormalities

Received: 04 February 2016
Accepted: 15 September 2016
Published: 03 October 2016

Kwaku Dad Abu-Bonsrah^{1,2}, Dongcheng Zhang^{1,2} & Donald F. Newgreen²

Chickens are an invaluable model for studying human diseases, physiology and especially development, but have lagged in genetic applications. With the advent of Programmable Engineered Nucleases, genetic manipulation has become efficient, specific and rapid. Here, we show that the CRISPR/Cas9 system can precisely edit the chicken genome. We generated *HIRA*, *TYRP1*, *DICER*, *MBD3*, *EZH2*, and 6 other gene knockouts in two chicken cell lines using the CRISPR/Cas9 system, with no off-target effects detected. We also showed that very large deletions (>75 kb) could be achieved. We also achieved targeted modification by homology-directed repair (HDR), producing *MEN2A* and *MEN2B* mutations of the *RET* gene. We also targeted *DGCR8* in neural cells of the chicken embryo by *in vivo* electroporation. After FACS isolation of transfected cells, we observed appropriate sequence changes in *DGCR8*. Wholemount and frozen section antibody labelling showed reduction of *DGCR8* levels in transfected cells. In addition, there was reduced expression levels of *DGCR8*-associated genes *DROSHA*, *YPEL1* and *NGN2*. We also observed morphological differences in neural tissue and cardiac-related tissues of transfected embryos. These findings demonstrate that precisely targeted genetic manipulation of the genome using the CRISPR/Cas9 system can be extended to the highly adaptable *in vivo* chicken embryo model.

Avian embryos, chiefly the chicken (*Gallus gallus*) and quail (*Coturnix japonica*), have been a mainstay of vertebrate embryologic research for over a century¹. The avian embryo is easy to obtain cheaply in large numbers as a result of its commercial utility. Development of avian embryos is simple to synchronise with little individual variation and benefits from excellent tables of development. Because development is external, these embryos are accessible to experimental manipulation². The similarity in the general ontogeny and gene expression patterns between avian embryos and those of other vertebrates including mouse embryos indicates that Aves can serve as an excellent model for the study of genetic, molecular and biochemical mechanisms in mammals including humans. Avian models have been especially useful in following developmental pathways, for example in tracking cell movements in morphogenesis, untangling inductive pathways and deciphering differentiation pathways. The results of these have been shown to be valid for other vertebrates³. Avian embryos have also been instructive in pathogenesis of embryonic diseases, and also physiology, behaviour and toxicology^{4,5}.

Avian embryology has lagged in genetic research partly because the commercial utility of poultry factored against collection of instructive mutants (as in the fly, fish and mouse) and partly because of the dearth of techniques to manipulate their genome. The introduction of *in vivo* transfection by electroporation and by viral vectors changed this dramatically, and allowed a form of conditional mutagenesis that was cheap and rapid⁶. Great ingenuity has enabled up- and down-regulation of genes to be achieved in avian embryos⁷, but these techniques largely involved adding extra genetic information in a non-targeted way, in the form of plasmids or miRNAs, either episomally, or by means that randomly integrate into the host genome⁸.

Programmable engineered nucleases (PENs) are novel technologies developed to efficiently target and alter a specific allele in the genome. These PENs, the zinc finger nucleases (ZFNs), the transcription activator-like effector nucleases (TALENs) and the clustered regular interspaced palindromic repeats (CRISPR)/Cas9 system, have

¹Department of Paediatrics, University of Melbourne, Parkville 3052, Australia. ²Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, 3052, Australia. Correspondence and requests for materials should be addressed to D.F.N. (email: don.newgreen@mcri.edu.au)




Figure 1. *In vitro* analysis of NHEJ and HDR genome modification (arrows) mediated by sgRNA-Cas9 system in chicken cell lines. (a) Frequency (%) of NHEJ mutation mediated by *KIAA1279*, *Cdkn1b* and *Mbd3*-targeting sgRNA-Cas9 system in chicken DF-1 cells by PCR and T7E1 assay. 1kM- 1 kbp DNA ladder, M- 100 bp DNA ladder. (b) Frequency (%) of NHEJ mutation mediated by *KIAA1279* and *Cdkn1b*-targeting sgRNA-CRISPR/Cas9 system in chicken lymphoma B DT40 cells by PCR and T7E1 assay. (c) Representative gel from DF-1 cells transfected with the RET-targeting sgRNA-Cas9 and the ssODN showing efficient integration of the HDR-based BamHI and EcoRV sequence. The frequency of HDR is represented in percentages. 1-No sgRNA, 2-MEN2B sgRNA #1 plus ssODN, 3- MEN2B sgRNA #1 and #2 plus ssODN and 4- MEN2A/HSCR sgRNA 1 plus ssODN. (d) Representative gel for single cell clones derived from DF-1 cells transfected with the RET-targeting sgRNA-Cas9 and the ssODN for the MEN2B and MEN2A/HSCR HDR modifications respectively. The table shows the ratio of the monoallelic and biallelic HDR-based mutations detected with single cell clones and the overall efficiency in percentage: N = 19 for MEN2B and N = 12 for MEN2A/HSCR.

been used extensively in generating and correcting mutations in cells of plants⁹, humans^{10,11}, rodents^{12,13}, monkeys^{14,15}, fish^{16–18}, fly^{19,20} and worm²¹ *in vitro* and *in vivo*, to generate transgenic cells, animals and plants. Recently, Park *et al.* validated the efficiency of TALENs in generating knockout chicken primordial germ cells (PGCs)²² and showed that TALENs can be used to efficiently modify the genomes of chickens. Here we utilise the recently described CRISPR/Cas9 system, which is a very simple but powerful tool in the editing *in vivo* of the genomes of mice^{23,24}, in knocking-out and knocking-in of sequences in chicken cells *in vitro* and *in vivo*.

Results

A recent report showed that the gene *Pax7* could be modified by CRISPR/Cas9 in the chicken embryo *in vivo*²⁵. To explore the general applicability of this technique, we investigated a range of chicken genes on both macrochromosomes and on the unusual avian microchromosomes. The genes chosen were *DROSHA*, *DICER*, *MBD3*, *KIAA1279*, *CDKN1B*, *EZH2*, *HIRA*, *TYRP1*, *STMN2*, *RET* and *DGCR8* (Di George Critical Region8) (Supplementary Table 1). These genes have roles in embryonic development and the pathogenesis of embryonic diseases.

The CRISPR/Cas9 system mediates NHEJ and HDR gene disruptions in chicken cell lines. We validated the activity of the CRISPR/Cas9 system by designing sgRNAs (Supplementary Table 2) targeting the translational initiation region (start codon) of *DROSHA*, *DICER*, *MBD3*, *KIAA1279*, *CDKN1B* and *EZH2*. We generated NHEJ-induced mutation by co-transfecting the sgRNA CRISPR/Cas9 construct with or without a puromycin resistance-expressing construct into the chicken fibroblastic DF-1 cell line using Lipofectamine 3000 (Fig. 1a). Genomic DNA was isolated after 72–96 hrs and the frequency of induced mutation in the targeted locus was analysed using the T7E1 assay and DNA sequencing (Supplementary Table 3). In puromycin-resistant cells, cleavage bands ranging between 20–68% were visible in all target genes as calculated by Image J software. The mutation efficiency induced was, for example, 50–51% in *KIAA1279*, 26–49% in *CDKN1B*, 68% in *MBD3* (Fig. 1a), 58% in *DICER* and 38% in *EZH2* genes (Supplementary Fig. 1B). We further characterised




Figure 2. Targeted deletion of large genomic fragments and off-target effect analysis in chicken cells *in vitro*. (a) Representative gels showing the large genomic deletions within the *STMN2* locus (>24 kbp) in chicken DF-1 and DT40 lymphoma B cells, and within the *RET* (>8 kbp) and *HIRA-DGCR8* locus (>70 kbp). (b) Frequency of off-target effects mediated by *RET-MEN2B* and *MEN2A/HSCR*, *CDKN1B*, *KIAA1279* and *STMN2*-targeting sgRNA-CRISPR/Cas9 system system in chicken DF-1 cells and *CDKN1B* and *KIAA1279*-targeting sgRNA-CRISPR/Cas9 system in DT40 cells by PCR and T7E1 assay. ND-not detected, 1 kM- 1 kbp DNA ladder.

cleavage by sequencing and this showed different indels detected at all the target sites with various mutation sizes (Supplementary Fig. 1D). We also targeted *KIAA1279*- and *CDKN1B*-with a different transfection method in a different cell line, using electroporation of the chicken B cell DT40 cell line, with similar results (Fig. 1b).

The CRISPR/Cas9 system precisely edits genes in chicken cell lines. Next, to test whether specific gene editing through HDR could be generated by the CRISPR/Cas9 system, we chose exons 10 and 16 of the *RET* gene which harbour, respectively, the mutation causing Multiple Endocrine Neoplasia 2A (*MEN2A*) and Hirschsprung disease (*MEN2A/HSCR*: C620R in humans and C612R in chickens) and *MEN2B* (M918T in humans and M910T in chickens) (Supplementary Fig. 1A)^{26,27}. We designed ssODNs with restriction enzyme site creation and disruption and co-transfected the sgRNA-CRISPR/Cas9 construct with the ssODN and the puromycin construct into the DF-1 cell line, using Lipofectamine 3000. Genomic DNA was isolated from 72–96 hrs post-transfected cells and the frequency of HDR-mediated genetic modification was analysed by digesting the PCR product with *EcoRV* and *BamHI* restriction enzymes. The digested bands indicate the frequency of HDR-mediated genetic modification from the ssODN template, which ranged between 34–66% of puromycin-resistant cells (Fig. 1c). Single clonal analysis shows the efficiency of biallelic and monoallelic HDR-mediated genetic modification by the CRISPR/Cas9 system as confirmed by gel and sequencing; 75% monoallelic with no biallelic for *MEN2A/HSCR* clones and 26% monoallelic and 21% biallelic for *MEN2B* clones (Fig. 1d).

The CRISPR/Cas9 system mediates larger genomic deletions in chicken cell lines. To see whether the CRISPR/Cas9 could also be used for large genomic fragment manipulation, we designed two sgRNAs targeting exon 1 and exon 3 of the *STMN2* gene which spans >24 kilobase pairs (kbps), exon 10 and exon 18 of the *RET* gene which spans >11 kbp, and exon 1 and 2 of *DGCR8* gene and exon 1 of *HIRA* genes which spans >75 kbps of the chicken genome (Supplementary Table 2). We first co-transfected the two sgRNAs in DF-1 cells and analysed the targeted deletion by PCR after genomic DNA extraction. The PCR results (Fig. 2a) shows that the CRISPR/Cas9 system can mediate large genomic deletions (frequency 15%) in chicken cells *in vitro* which is in concordance with published data for other species^{18,28,29}. We then further applied this approach to the chicken DT40 cell line, targeting the *STMN2* locus, and sequencing confirmed the >24 kbp deletion within this locus.

The CRISPR/Cas9 system produces no detectable off-target effects in chicken cell lines. Off-target mutagenesis remains a draw-back in the use of PENS, and in human cells the CRISPR/Cas9 system has been reported to have relatively high off-target effects compared to other PENS^{30–32}. Potential off-target sites with higher scores using the crispr.mit.edu software were selected and analysed by T7E1 assay in both the chicken DF-1 cells and the DT-40 cells of the *KIAA1279* and *CDKN1B*-targeting sgRNA-CRISPR/Cas9 constructs and that of the HDR experiments targeting *RET* in DF-1 cells (Fig. 2b). There were no detectable off-target effects and these results suggest that chicken cells can potentially serve as a model for the use of the CRISPR/Cas9 nuclease, which is known for off-target effects in the human context.

The CRISPR/Cas9 system can act efficiently without selection in chicken cell lines. Drug selection cannot be used in *in vivo* applications so we investigated whether acceptable gene modification efficiency can be obtained without puromycin selection. sgRNA activity and hence efficiency of mutation-induction can be affected by target locus location, chromatin structure, and nucleotide preferences³³. Our results show that drug selection for the CRISPR/Cas9 system in chickens is not a necessity but can however improve efficiencies for some sgRNAs with low targeting efficiencies (Supplementary Fig. 1C).

CRISPR/Cas9 mediates somatic cell modification in chicken embryonic cells *in vivo*. Genetic engineering techniques in chicken have been the genomic modification of PGCs with a germ-line transmission capacity using the lentiviral system^{34,35} or Piggybac transposon vector^{34,36}. Recent work by Park *et al.* showed that TALENs can efficiently generate knockout of targeted genes in chicken cells and in PGCs^{4,22}. We then tested the efficiency of the CRISPR/Cas9 system in introducing NHEJ mutations into the avian embryo by *in vivo* electroporation. *In vivo* electroporation is a useful tool for the study of spatio-temporal gene functions, since the manipulation of genes can be used to study the roles of such genes in a restricted region during specific developmental stages^{4,6}.

We injected and electroporated the *DGCR8* exon 2-targeting sgRNA-CRISPR/Cas9 plasmid vectors incorporating mCherry marker *in vivo* into E1.5 embryo cranial neural tube, which transfects the brain and cranial neural crest (Supplementary Fig. 2A). *DGCR8* is involved in miRNA processing and the targeted mutation should abrogate the gene function (Supplementary Fig. 2B). We also co-electroporated Tol2-GFP/transposase construct to indicate the trend and variability of transfection where neural crest cells migrate out of the neural tube to surround the brain and eye, and migrate to the branchial arches and facial mesoderm (Supplementary Fig. 2A). Note that for this technique, the distribution and number of transfected cells, as shown by the extent of GFP expressing cells, is variable³⁷.

After embryo electroporation with the CRISPR/Cas9 construct, we analysed the hindbrain and midbrain by whole mount immunofluorescence for *DGCR8* expression. Since the mCherry plasmid is episomal, expression of mCherry is transient^{37,38}, embryos were harvested after two days and immunostained with mCherry and *DGCR8* antibodies (unelectroporated embryos, N = 8; electroporated embryos N = 24). Electroporated (i.e. mCherry-positive) cells in the midbrain, hindbrain and eye region showed a decrease in *DGCR8* expression as determined by decrease in *DGCR8* immunofluorescent intensity measured by pixel-count from confocal images (Fig. 3a,b). It is important to mention that *DGCR8* expression in postnatal mouse brain has a major nuclear location (Supplementary Fig. 4A), but mainly cytoplasmic location was observed in embryonic chick brain cells (Fig. 3a). Subcellular heterogeneity of location has been reported for *DGCR8*³⁹. In addition *DGCR8*'s binding partner Droscha also shows cytoplasmic as well as nuclear localisation⁴⁰. The neuronal RNA-binding proteins HUC/D also have different localisation patterns in rodent and chicken cells (compare figures in Hao *et al.*⁴¹ and Rollo *et al.*⁴²). Western blotting of postnatal mouse and embryonic chick brain showed identical *DGCR8*-immunoreactive protein bands of appropriate molecular weight (Supplementary Fig. 4B), in accord with the high predicted sequence homology between the two species (NCBI database).

In addition, electroporated embryos (N = 34) and control embryos (N = 85) were harvested after four days. The control embryos were used to gauge the background effects of the electroporation technique. The controls were sham-treated non-electroporated embryos (i.e. eggs opened, embryos visualised with India Ink, vitelline membrane nicked and eggs resealed; N = 23), embryos electroporated but without plasmids (i.e. non-transfected; N = 11), embryos electroporated and transfected with the benign Tol2-GFP/transposase plasmids (N = 29), embryos electroporated with the Cas9 construct targeting the unrelated *STMN2* gene (N = 14) and embryos electroporated with the empty Cas9 construct (Cas9 vector with no cloned guide sequence; N = 8).

As expected, after 4 days mCherry fluorescence in wholemount embryos had declined to a level undetectable with the fluorescence stereomicroscope but we could FACs sort cells (mCherry^{low} and mCherry^{high}) from the hindbrain. We performed T7E1 and qPCR analysis on these cells and showed a loss of *DGCR8* mRNA levels in mCherry^{high} sorted cells which was confirmed by sequence analysis (Supplementary Fig. 2B). *DGCR8* sgRNA -CRISPR/Cas9 induced nucleotide deletions at the targeted locus with 1–5 bp deletions and insertions. In most clones this formed a stop codon which would result in nonsense-mediated decay of the *DGCR8* mRNA (Supplementary Fig. 2B). The qPCR results coupled with the sequence data suggest a drastic decrease in *DGCR8* gene expression in these brain cells during development, which could delay or disturb the growth of the midbrain as a whole. In addition the expression level of several other genes were analysed with findings consistent with previous findings (Supplementary Fig. 3A)^{43–46}. Of the 34 *DGCR8*-targeted transfected embryos, 8 had a reduced head size and distorted morphology exemplified by major reduction of the midbrain (Fig. 4a). They also showed a reduction in their eyes: it has been reported earlier that miRNAs play an essential role in the differentiation of the retinal pigmented epithelium⁴⁷. Furthermore, we compared the morphology of the hearts of the *DGCR8*-targeted embryos to the control embryos since in the *DGCR8* mutant mouse, decreased *DGCR8* expression results in a spectrum of malformations and reductions in cardiovascular development⁴⁸. We observed deformations in the




Figure 3. Protein expression 2 days after transfection with *DGCR8* CRISPR/Cas9 construct.

(a) Immunofluorescence confocal images of single and merged channels of the indicated markers from whole mount staining of *DGCR8* mutant embryos, indicating reduced to no *DGCR8* expression in transfected (mCherry+) cells (shown by yellow arrows). (b) Histogram of pixel counts on control embryos and *DGCR8* mutants embryos relative to DAPI. A total of 540 cells and 542 (≥ 100 cells/embryo) were counted from 5 control and 6 electroporated embryos respectively. The low fluorescence in the mCherry waveband in controls is tissue autofluorescence. Scale bar: 5 μm. Error bars, mean \pm s.e.m. * $P < 0.05$, *** $P < 0.001$.

heart and outflow tract in 14 embryos (41.2%) of the transfected embryos. It is important to note that none of the 85 control embryos had these cranial, retinal and cardiac abnormalities (Fig. 4a,b).

These findings provide further support that the chicken embryo can be genetically modified *in vivo* in a targeted and sophisticated way to study disease models in developing embryos.

Discussion

The chick embryo is not only an excellent and reproducible system for embryonic developmental studies but also its accessibility and versatility makes it an alternative model in research directly relatable to humans and other animals. We have shown that the CRISPR/Cas9 system can modify multiple genes on both avian macro- and microchromosomes at acceptable efficiency with or without selection, with no detectable off-target effects, a previously mentioned drawback in the use of the CRISPR/Cas9 system⁴⁹.

The function of genes can be spatio-temporally studied using CRISPR/Cas9 system *in vivo* provided that selection is not required. A recent example uses viral delivery to the adult mouse brain⁵⁰. Moreover, refinements to increase the efficiency⁵¹ and limit the off-target errors^{52,53} are progressing rapidly. This means that for developmental studies, the advantages of the chick embryo as an accessible model and the convenience of *in vivo* electroporation at chosen developmental stages and locations can be combined with the power of CRISPR/Cas9 gene editing. We confirm this prediction here, extending the previous trial with *Pax7*²⁵.

In vivo transfection, including *in vivo* electroporation, affects a modest and variable proportion of cells³⁷. This means that, as in many *DGCR8* electroporated embryos, a gross phenotype will not be observed in every instance since gross phenotypic change depends on high mutational load^{54,55}. Despite this, functional effects of the genetic modification at the cellular level *in vivo* can be accurately gauged by imaging mutated cells and comparing with non-modified control cells in the same specimen. This requires markers of both the transfected cells and their otherwise similar control cells.

An interesting application of CRISPR/Cas9 editing would be the study of genes involved in nervous system development⁵⁶, organogenesis and structural patterning. An important application would be to modify genes for growth factor response, proliferation or differentiation in neural crest cells. A specific clinically relevant example is the effect of *MEN2* mutations which induce a variety of neurocristopathies and developmental cancers⁵⁷. In addition, targeting of primordial germ cells by CRISPR/Cas9 offers the hope of genetically engineering avian models with any desired gene variant.




Figure 4. Somatic targeted genetic modification by CRISPR/Cas9 system in chickens 4 days after *in vivo* electroporation. (a) Frequency (%) of NHEJ mutation mediated by *DGCR8*-targeting sgRNA-CRISPR/Cas9 system in DF-1 cells by PCR. Red arrows indicate the NHEJ mutation created by the CRISPR/Cas9 system. M- 100bp DNA ladder. Representative images of sham treated (con), electroporated untransfected embryos (electro.), Tol2 GFP transfected embryos (GFP transflect) with normal head development and *DGCR8* CRISPR/Cas9 transfected embryos (D1 and D2) showing midbrain (open arrow) and eye (closed arrow) abnormalities. Graph shows the difference in the midbrain dimensions of *DGCR8* mutant embryos compared to control embryos- $N = 14$. (b) Representative image of the hearts of unelectroporated embryos, electroporated with no construct embryos, Tol2 GFP and empty Cas9 transfected embryos, *STMN2* transfected embryos (negative control) showing normal heart development, and *DGCR8* transfected embryos showing misshapen and reduced hearts. (c) qPCR analysis of cells isolated by FACS from *DGCR8*-targeted embryos demonstrating the reduced mRNA levels of *DGCR8* in mCherry⁺ brain cells (M) relative to negatively sorted cells (N). Normalisation was done with ACTB and RPL32. ND-not detected. Error bars, mean \pm s.e.m. *** $P < 0.001$.

In conclusion, we have shown that transiently expressing the CRISPR/Cas9 construct can mediate genetic modification of avian embryonic somatic cells, reducing mRNA levels and generating phenotypes in the whole embryo. These results are in congruence with recent work also showing the efficiency of genome editing of post-natal mice using the CRISPR/Cas9 system⁵⁸.

Methods

Ethics Statement. All experiments were performed with the official approval from the Murdoch Childrens Research Institute Animal Ethics Committee AEC650 and AEC677 and Institutional Biosafety Committee 226–2015 PC2 NLRD and in strict accordance with its guidelines and those of the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, 7TH Edition 2004 and the Prevention of Cruelty to Animals Act, Victoria 1986.

sgRNA-CRISPR/Cas9 system design and construction. Potential target sites were predicted using crispr.mit.edu software in the chicken genome and two to three target sequences with lower predicted score for off-targets were chosen. To construct the sgRNA-CRISPR/Cas9 construct for each target gene, we annealed two complementary 24-bp oligonucleotides (Bioneer Company, South Korea) with the 20-bp target sequence to generate a double-strand DNA with 4-bp overhangs on both ends and cloned into BsaI-digested px330-IRES-mCherry. Oligonucleotides are listed in Supplementary Table 2.

DF-1 cell culture and transfection. The chicken DF-1 cell⁵⁹ line was maintained and sub-passaged in DMEM (Thermo Scientific), supplemented with 10% fetal bovine serum (FBS; GIBCO) and 1 × penicillin/streptomycin (GIBCO), at 37 °C in 5% CO₂. Cells were seeded at 0.4–0.8 × 10⁵ cells/well in 24-well plates, incubated for 4 hrs, and then transfected with 1.5 μg CRISPR/Cas9 sgRNA targeting the specified gene or region and with or without 0.15 μg of puromycin expression vector using Lipofectamine 3000 (Invitrogen) according to the manufacturer's protocol with slight modifications. Briefly, 1 μL and 2 μL of Lipofectamine 3000 reagent was added to two different tubes with 25 μL of OPTI-MEM medium (Invitrogen) and briefly vortexed. Then a mixture of 1.5 μg of the CRISPR/Cas9-sgRNA plasmid (px330-IRES-mCherry), 0.15 μg puromycin expression vector and 3 μL of p3000 reagent (Invitrogen) in 50 μL OPTI-MEM was made and then 25 μL of the p3000-DNA complex was then added to each of the Lipofectamine 3000 complex tubes and incubated for 5 minute at room temperature. The complex mixture was then gently pipetted into a well of a 24-well plate with DF-1 cells at about 60–80% confluency. After 24 hrs post-transfection, the cells were treated with puromycin at a final concentration of 2 μg/mL for 2 days and the cells were allowed to recover for a day or two.

For HDR knock-ins, cells were transfected with 1.0 μg CRISPR/Cas9 sgRNA targeting the specified gene or region with 40 pmoles of ssODN and 0.15 μg of puromycin expression vector following the same protocol.

DT40 cell culture and transfection. Cells of the chicken B cell line DT40⁶⁰ were cultured in chicken medium composed of RPMI-1640 medium (Sigma Aldrich), 10% FBS, 1% chicken serum (Sigma) and penicillin/streptomycin, at 39 °C in 5% CO₂. A total of 1–2 × 10⁷ cells were pelleted at 1500 rpm for 3 min at room temperature and the pellet was washed with PBS and pelleted again. The pellet was then resuspended in 600 μL PBS and after the addition of 30 μg of sgRNA-CRISPR/Cas9 plasmid and 3 μg of puromycin expression vector, the resuspension was placed in a BioRad 4 mm electroporation cuvette. Electroporation was done using BioRad Gene Pulser II at 250 V and 950 μF. After electroporation, cells were mixed with 10 ml of culture medium without penicillin/streptomycin and cultured for 12–24 hrs. The cells were treated with puromycin at a final concentration of 2 μg/mL for a day and the cells were allowed to recover for 2–3 days.

T7E1 mutation frequency analysis. Samples of cells and embryos were collected and digested in nuclear lysis buffer (Promega, Madison, WI). Genomic DNA was extracted from DF-1 cells or DT40 cells after transfection of each CRISPR/Cas9-sgRNA. The genomic DNA was extracted from the lysate by phenol-chloroform and recovered by isopropanol precipitation. The genomic region encompassing the CRISPR/Cas9 target site was amplified with a specific primer set for each gene (Supplementary Table 3). The amplicons were re-annealed to form a heteroduplex DNA structure after denaturation and then treated with 2.5 units T7E1 (New England Biolabs, Ipswich, MA) for 20 min at 37 °C and then analyzed by 2% agarose gel electrophoresis. Mutation frequencies were calculated as previously described⁶¹ based on the band intensities using Image J software and the following equation: mutation frequency (%) = 100 × (1 – (1 – fraction cleaved)^{1/2}), where the fraction cleaved is the total relative density of the cleavage bands divided by the sum of the relative density of the cleavage bands and uncut bands. To confirm target locus mutation, PCR amplicons were cloned into a pGEM-T Easy vector (Promega, Madison, WI) and sequenced. Primers for the PCR analysis are listed in supplementary figures.

Restriction Enzyme digestion (RFLP). Six μL of the PCR product was digested with 0.5 μL of the required restriction enzyme in a 20 μL reaction and incubated for 4–8 hrs at 37 °C. For MEN2B HDR templates, the PCR products were digested in BamHI restriction enzyme (New England Biolabs, Ipswich, MA) and in EcoRV restriction enzyme (New England Biolabs, Ipswich, MA) for MEN2A/HSCR HDR experiments. Digested products were then analysed by 1.5% agarose gel electrophoresis. Positive clones were cloned into the pGEM-T Easy vector (Promega, Madison, WI) and cloned products were sequenced.

Sequencing analysis. PCR products were cloned into the pGEM-T Easy vector (Promega, Madison, WI) and cloned products were sequenced using the T7 promoter primer (5'-TAATACGACTCACTATAGGG-3').

Off-target prediction and analysis. Potential chicken *KIAA1279*, *CDKN1B*, *STMN2* and *RET* gene off-targets were predicted using crispr.mit.edu software in the chicken genome. Off-target site with scores more than 1 or with 2 or more mismatches were chosen and amplified by PCR using the extracted genomic DNA as templates. The PCR products were first subjected to T7E1 cleavage assay¹⁴. Oligonucleotides are listed in Supplementary Table 4.

Single cell clonal analysis. Cells were trypsinized and plated in 96 well plates at average 0.3 cell/well and incubated at 37 °C for two weeks. Each well was then microscopically evaluated, and single cell-derived clones were selected and expanded into 24 well plates. Genomic DNA from each clone was extracted and T7E1 assay was conducted following the above protocol. To confirm HDR of the ssODN, PCR amplicons were digested with 5 units of the restriction enzyme BamHI (New England Biolabs) for more than 2 hrs at 37 °C and then analysed on 2% agarose gel by electrophoresis. PCR amplicons of BamHI or T7E1 digested clones were cloned into a pGEM-T Easy vector (Promega, Madison, WI) and sequenced.

In vivo electroporation. Eggs from a cross breed *White Leghorn x Black Australorp* were commercially purchased (Research Hatchery, Victoria). *In vivo* electroporation were performed as previously described^{37,62,63}. The CRISPR/Cas9 *DGCR8* exon 2 targeting construct was co-electroporated with pT2K-CAAGGS-EGFP (termed Tol2-GFP) and pCAGGS-T2TP (transposase)³⁸ at 6:6:1.5 µg/µL ratio respectively. The plasmid mixture was prepared and coloured with 2% Fast Green and then microinjected forward from the 3–4 somite level of the neural tube into the hind and midbrain of E1.5 chicken embryos. Electric pulses of 10.5 V, 50 ms duration were delivered 3 times bilaterally with 175-ms intervals. Chicken embryos were harvested 2 and 4 days post-electroporation and processed for immunostaining and cell sorting.

Fluorescence Activated Cell Sorting. Cell suspensions from harvested embryos were made using 0.5% w/v Dispase II (Roche, Switzerland) and 0.1% w/v CLSAFA Collagenase (Worthington, USA) at 37 °C in Hams F12 solution for 5–10 minutes. The digested cells were pelleted and resuspended in PBS containing 2% FBS and strained (40 µm mesh; BD Falcon; Becton, Dickinson and Co., Franklin Lakes, NJ) and FACS sorted using the BD Influx Cell Sorter, with separation based on GFP and mCherry fluorophores.

RNA extraction and SYBR Green qPCR. Total RNA was extracted from sorted cells using the Trizol reagent (Invitrogen) and lysate were purified by the acid-phenol chloroform and recovered by isopropanol/ethanol precipitation method. Extracted RNA was digested with DNaseI (Promega) following the manufacturer's instructions to remove any residual DNA.

qPCR was performed to confirm the expression of *DROSHA*, *Neurogenin 2 (Ngn2)*, *Pax6*, *YP6L1*, and *DGCR8* genes in transfected modified embryonic cells from electroporated embryos. Briefly, 20 ng total RNA was converted into cDNA in the presence of SuperScript IV RT (Invitrogen) and random hexamers (Promega). Reactions were performed using cDNA converted from 10 ng of RNA, 250 nM of each primer and 2X SYBR Green qPCR Master Mix (Promega) in a total volume of 20 µL. Primers for qPCR analysis are listed in Supplementary Table 5. *ACTB* and *RPL32* were used for data normalization. mCherry-/GFP- sorted cells from each embryo were used as a calibrator and relative fold changes were calculated using the $2^{-[\Delta][\Delta]Cq}$ method.

Whole mount staining and immunohistochemistry. Embryos were harvested 2 days post electroporation (E3.5) and sagittally dissected, fixed in 4% paraformaldehyde in PBS at 4 °C overnight then washed in PBS three times. Embryos were blocked and permeabilised with 3% horse serum and 0.2% Triton-X100 in PBS/azide for 1 hr. Control cryostat 18 µm sections of chick embryo and post-natal mouse brain were also used. Rabbit anti-DGCR8 antibody (Abcam-ab82876) and mouse anti-mCherry (DSHB, Iowa City) at 1:200 and 1:100 respectively were applied in 1% horse serum and 0.1% Triton-X in PBS azide and incubated on a rocker at 4 °C overnight. The human *DGCR8* immunogen (N-terminal amino acids 180–229) was 89% identical to the predicted chick amino acid sequence (NCBI database), with all changes conservative. Washing with PBS was done for 3 hrs with changes every 30 minutes on a rocker at 4 °C. Secondary antibodies were donkey anti-rabbit:Alexa Fluor 488 for mouse sections (Life Technologies-1:1000) and donkey anti-rabbit:Cy5 plus donkey anti-mouse:Alexa Fluor 568 for whole mounts (Jacksons Immunoresearch-1:500 and 1:1000 respectively) and 500 ng/mL (1 in 100 of 50 µg/mL stock) DAPI was applied and incubated for 3 hrs on the rocker at 4 °C. Embryos were washed with PBS three times and mounted using DABCO/glycerol mounting medium. Confocal microscopy was performed using the Zeiss LSM 780 confocal microscope.

For cryostat sections, fixed embryo heads (E5.5) were placed in 30% sucrose in PBS overnight, embedded in Tissue Tek OCT Compound Medium in Tissue Tek cryomoulds (both from ProSciTech, Thuringowa, Australia) and frozen in dry ice-cooled isopentane. Eighteen µm sections were cut transversely using a Leica CM 1900 cryostat microtome and collected on Superfrost microscope slides (Biolab Scientific, Auckland, NZ) coated with poly-L-lysine. Mouse post-natal brains were also fixed, sectioned, mounted and stained as above.

Western Blotting. Brains from chick embryos (E6) were homogenised in 2 mL of sample buffer for SDS-PAGE. Homogenates were sonicated for 40 sec and centrifuged at 13,000 rpm for 5 min. The resulting supernatants were divided into 100 µL aliquots and stored at –80 °C. Protein concentration of 3.3% homogenates (w/v) in PBS was determined by the Pierce BCA Protein Assay Kit (ThermoFisher Scientific) using bovine serum albumin as a standard. Forty micrograms of each sample were analyzed by Western blotting. The apparent molecular mass of *DGCR8* was estimated by a prestained protein marker (Life Technologies). Control tissue was obtained from post-natal mouse brain.

Relative Pixel Quantification. Standard confocal images were selected and analysed using the Zeiss Image Analyser. Regions of interest were selected with the Free-Hand tool and choosing the DAPI channel, the cells in a field were counted and relative pixel quantification was calculated following a previous publication⁶⁴. Relative fluorescence intensity was calculated by normalising the mCherry and *DGCR8* expression to DAPI intensity.

Statistical analyses. Data were analyzed by the unpaired t test with Welch's correction. Values were expressed as mean ± SEM. Changes were deemed significant if the p value was >0.05. Statistical significance is indicated as follows: **p* > 0.05, ***p* > 0.01, and ****p* > 0.001. Graphs were drawn using Microsoft Excel and GraphPad Prism.

References

- Mason, I. The avian embryo: an overview. *Methods Mol Biol* **461**, 223–230, doi: 10.1007/978-1-60327-483-8_14 (2008).
- Niswander, L. Methods in avian embryology experimental and molecular manipulation of the embryonic chick limb. *Methods in cell biology* **87**, 135–152, doi: 10.1016/S0091-679X(08)00207-0 (2008).

3. Le Douarin, N. M. & Dieterlen-Lievre, F. How studies on the avian embryo have opened new avenues in the understanding of development: a view about the neural and hematopoietic systems. *Development, growth & differentiation* **55**, 1–14, doi: 10.1111/dgd.12015 (2013).
4. Park, T. S., Kang, K. S. & Han, J. Y. Current genomic editing approaches in avian transgenesis. *General and comparative endocrinology* **190**, 144–148, doi: 10.1016/j.ygcen.2012.11.020 (2013).
5. Smith, S. M., Flentke, G. R. & Garic, A. Avian models in teratology and developmental toxicology. *Methods Mol Biol* **889**, 85–103, doi: 10.1007/978-1-61779-867-2_7 (2012).
6. Itasaki, N., Bel-Vialar, S. & Krumlauf, R. ‘Shocking’ developments in chick embryology: electroporation and in ovo gene expression. *Nat Cell Biol* **1**, E203–207 (1999).
7. Sauka-Spengler, T. & Barembaum, M. Gain- and loss-of-function approaches in the chick embryo. *Methods in cell biology* **87**, 237–256, doi: 10.1016/S0091-679X(08)00212-4 (2008).
8. Takahashi, Y., Watanabe, T., Nakagawa, S., Kawakami, K. & Sato, Y. Transposon-mediated stable integration and tetracycline-inducible expression of electroporated transgenes in chicken embryos. *Methods in cell biology* **87**, 271–280, doi: 10.1016/S0091-679X(08)00214-8 (2008).
9. Shan, Q., Wang, Y., Li, J. & Gao, C. Genome editing in rice and wheat using the CRISPR/Cas system. *Nature protocols* **9**, 2395–2410, doi: 10.1038/nprot.2014.157 (2014).
10. Hou, Z. *et al.* Efficient genome engineering in human pluripotent stem cells using Cas9 from *Neisseria meningitidis*. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 15644–15649, doi: 10.1073/pnas.1313587110 (2013).
11. Yang, L. *et al.* Optimization of scarless human stem cell genome editing. *Nucleic acids research* **41**, 9049–9061, doi: 10.1093/nar/gkt555 (2013).
12. Zhang, Y., Vanoli, F., LaRocque, J. R., Krawczyk, P. M. & Jasin, M. Biallelic targeting of expressed genes in mouse embryonic stem cells using the Cas9 system. *Methods* **69**, 171–178, doi: 10.1016/j.ymeth.2014.05.003 (2014).
13. Shao, Y. *et al.* CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos. *Nature protocols* **9**, 2493–2512, doi: 10.1038/nprot.2014.171 (2014).
14. Niu, Y. *et al.* Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. *Cell* **156**, 836–843, doi: 10.1016/j.cell.2014.01.027 (2014).
15. Shen, H. Precision gene editing paves way for transgenic monkeys. *Nature* **503**, 14–15, doi: 10.1038/503014a (2013).
16. Shin, J., Chen, J. & Solnica-Krezel, L. Efficient homologous recombination-mediated genome engineering in zebrafish using TALE nucleases. *Development* **141**, 3807–3818, doi: 10.1242/dev.108019 (2014).
17. Auer, T. O. & Del Bene, F. CRISPR/Cas9 and TALEN-mediated knock-in approaches in zebrafish. *Methods* **69**, 142–150, doi: 10.1016/j.ymeth.2014.03.027 (2014).
18. Ota, S., Hisano, Y., Ikawa, Y. & Kawahara, A. Multiple genome modifications by the CRISPR/Cas9 system in zebrafish. *Genes to cells: devoted to molecular & cellular mechanisms* **19**, 555–564, doi: 10.1111/gtc.12154 (2014).
19. Bassett, A. R. & Liu, J. L. CRISPR/Cas9 and genome editing in *Drosophila*. *Journal of genetics and genomics = Yi chuan xue bao* **41**, 7–19, doi: 10.1016/j.jgg.2013.12.004 (2014).
20. Gokcezade, J., Sienski, G. & Duchek, P. Efficient CRISPR/Cas9 plasmids for rapid and versatile genome editing in *Drosophila*. *G3* **4**, 2279–2282, doi: 10.1534/g3.114.014126 (2014).
21. Chen, C., Fenk, L. A. & de Bono, M. Efficient genome editing in *Caenorhabditis elegans* by CRISPR-targeted homologous recombination. *Nucleic acids research* **41**, e193, doi: 10.1093/nar/gkt805 (2013).
22. Park, T. S., Lee, H. J., Kim, K. H., Kim, J. S. & Han, J. Y. Targeted gene knockout in chickens mediated by TALENs. *Proc Natl Acad Sci USA* **111**, 12716–12721, doi: 10.1073/pnas.1410555111 (2014).
23. Long, C. *et al.* Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. *Science* **351**, 400–403, doi: 10.1126/science.aad5725 (2016).
24. Nelson, C. E. *et al.* *In vivo* genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. *Science* **351**, 403–407, doi: 10.1126/science.aad5143 (2016).
25. Veron, N., Qu, Z., Kipen, P. A., Hirst, C. E. & Marcelle, C. CRISPR mediated somatic cell genome engineering in the chicken. *Developmental biology* **407**, 68–74, doi: 10.1016/j.ydbio.2015.08.007 (2015).
26. Smith, D. P., Houghton, C. & Ponder, B. A. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. *Oncogene* **15**, 1213–1217, doi: 10.1038/sj.onc.1201481 (1997).
27. Gimm, O. *et al.* Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. *The Journal of clinical endocrinology and metabolism* **82**, 3902–3904, doi: 10.1210/jcem.82.11.4508 (1997).
28. He, Z. *et al.* Highly efficient targeted chromosome deletions using CRISPR/Cas9. *Biotechnology and bioengineering* **112**, 1060–1064, doi: 10.1002/bit.25490 (2015).
29. Xiao, A. *et al.* Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. *Nucleic acids research* **41**, e141, doi: 10.1093/nar/gkt464 (2013).
30. Hsu, P. D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nature biotechnology* **31**, 827–832, doi: 10.1038/nbt.2647 (2013).
31. Pattanayak, V. *et al.* High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. *Nature biotechnology* **31**, 839–843, doi: 10.1038/nbt.2673 (2013).
32. Fu, Y. *et al.* High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nature biotechnology* **31**, 822–826, doi: 10.1038/nbt.2623 (2013).
33. Doench, J. G. *et al.* Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. *Nature biotechnology* **32**, 1262–1267, doi: 10.1038/nbt.3026 (2014).
34. Park, S. H. *et al.* CpG methylation modulates tissue-specific expression of a transgene in chickens. *Theriogenology* **74**, 805–816 e801, doi: 10.1016/j.theriogenology.2010.04.005 (2010).
35. Motono, M. *et al.* Production of transgenic chickens from purified primordial germ cells infected with a lentiviral vector. *Journal of bioscience and bioengineering* **109**, 315–321, doi: 10.1016/j.jbiosc.2009.10.007 (2010).
36. Kubo, F., Takeichi, M. & Nakagawa, S. Wnt2b inhibits differentiation of retinal progenitor cells in the absence of Notch activity by downregulating the expression of proneural genes. *Development* **132**, 2759–2770, doi: 10.1242/dev.01856 (2005).
37. Simkin, J. E., Zhang, D., Ighaniyan, S. & Newgreen, D. F. Parameters affecting efficiency of in ovo electroporation of the avian neural tube and crest. *Developmental dynamics: an official publication of the American Association of Anatomists* **243**, 1440–1447, doi: 10.1002/dvdy.24163 (2014).
38. Sato, Y. *et al.* Stable integration and conditional expression of electroporated transgenes in chicken embryos. *Developmental biology* **305**, 616–624, doi: 10.1016/j.ydbio.2007.01.043 (2007).
39. Nakano, A., Onohara, Y., Yokota, S. & Fujita, H. DGCR8 Localizes to the Nucleus as well as Cytoplasmic Structures in Mammalian Spermatogenic Cells and Epididymal Sperm. *Journal of Histology* **2013**, 11, doi: 10.1155/2013/414891 (2013).
40. Link, S., Grund, S. E. & Diederichs, S. Alternative splicing affects the subcellular localization of Droscha. *Nucleic acids research* **44**, 5330–5343, doi: 10.1093/nar/gkw400 (2016).
41. Hao, M. M. *et al.* Enteric nervous system assembly: Functional integration within the developing gut. *Developmental biology*, doi: 10.1016/j.ydbio.2016.05.030 (2016).
42. Rollo, B. N., Zhang, D., Simkin, J. E., Menhenniott, T. R. & Newgreen, D. F. Why are enteric ganglia so small? Role of differential adhesion of enteric neurons and enteric neural crest cells. *F1000Research* **4**, 113, doi: 10.12688/f1000research.6370.1 (2015).

43. Fan, P. *et al.* miRNA biogenesis enzyme Drosha is required for vascular smooth muscle cell survival. *PLoS one* **8**, e60888, doi: 10.1371/journal.pone.0060888 (2013).
44. Wang, Y., Medvid, R., Melton, C., Jaenisch, R. & Blleloch, R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. *Nature genetics* **39**, 380–385, doi: 10.1038/ng1969 (2007).
45. Boyer, L. A. *et al.* Polycomb complexes repress developmental regulators in murine embryonic stem cells. *Nature* **441**, 349–353, doi: 10.1038/nature04733 (2006).
46. Klein, M. E. *et al.* Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. *Nature neuroscience* **10**, 1513–1514, doi: 10.1038/nn2010 (2007).
47. Ohana, R. *et al.* MicroRNAs are essential for differentiation of the retinal pigmented epithelium and maturation of adjacent photoreceptors. *Development* **142**, 2487–2498, doi: 10.1242/dev.121533 (2015).
48. Chapnik, E., Sasson, V., Blleloch, R. & Hornstein, E. Dgcr8 controls neural crest cells survival in cardiovascular development. *Developmental biology* **362**, 50–56, doi: 10.1016/j.ydbio.2011.11.008 (2012).
49. Park, T. S. & Han, J. Y. Genetic modification of chicken germ cells. *Annals of the New York Academy of Sciences* **1271**, 104–109, doi: 10.1111/j.1749-6632.2012.06744.x (2012).
50. Swiech, L. *et al.* *In vivo* interrogation of gene function in the mammalian brain using CRISPR-Cas9. *Nature biotechnology* **33**, 102–106, doi: 10.1038/nbt.3055 (2015).
51. Chu, V. T. *et al.* Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nature biotechnology* **33**, 543–548, doi: 10.1038/nbt.3198 (2015).
52. Kim, D. *et al.* Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells. *Nature methods* **12**, 237–243, 231 p following 243, doi: 10.1038/nmeth.3284 (2015).
53. Kleinstiver, B. P. *et al.* High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature*, doi: 10.1038/nature16526 (2016).
54. Shah, A. N., Davey, C. F., Whitebirch, A. C., Miller, A. C. & Moens, C. B. Rapid reverse genetic screening using CRISPR in zebrafish. *Nature methods* **12**, 535–540, doi: 10.1038/nmeth.3360 (2015).
55. Sung, Y. H. *et al.* Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases. *Genome research* **24**, 125–131, doi: 10.1101/gr.163394.113 (2014).
56. Heidenreich, M. & Zhang, F. Applications of CRISPR-Cas systems in neuroscience. *Nature reviews. Neuroscience* **17**, 36–44, doi: 10.1038/nrn.2015.2 (2016).
57. Zhang, D. *et al.* The neural crest: a versatile organ system. *Birth defects research. Part C, Embryo today: reviews* **102**, 275–298, doi: 10.1002/bdrc.21081 (2014).
58. Long, C. *et al.* Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. *Science*, doi: 10.1126/science.aad5725 (2015).
59. Lambeth, L. S., Cummins, D. M., Doran, T. J., Sinclair, A. H. & Smith, C. A. Overexpression of aromatase alone is sufficient for ovarian development in genetically male chicken embryos. *PLoS one* **8**, e68362, doi: 10.1371/journal.pone.0068362 (2013).
60. Kim, J. H. *et al.* Condensin I associates with structural and gene regulatory regions in vertebrate chromosomes. *Nature communications* **4**, 2537, doi: 10.1038/ncomms3537 (2013).
61. Guschin, D. Y. *et al.* A rapid and general assay for monitoring endogenous gene modification. *Methods Mol Biol* **649**, 247–256, doi: 10.1007/978-1-60761-753-2_15 (2010).
62. Sato, Y., Yasuda, K. & Takahashi, Y. Morphological boundary forms by a novel inductive event mediated by Lunatic fringe and Notch during somitic segmentation. *Development* **129**, 3633–3644 (2002).
63. Yokota, Y., Saito, D., Tadokoro, R. & Takahashi, Y. Genomically integrated transgenes are stably and conditionally expressed in neural crest cell-specific lineages. *Developmental biology* **353**, 382–395, doi: 10.1016/j.ydbio.2011.02.001 (2011).
64. Oriol Arqués, I. C., Stephan, T., Isabel, P. & Héctor, G. Palmer. Standardized Relative Quantification of Immunofluorescence Tissue Staining. *Nature Protocol Exchange*, doi: 10.1038/protex.2012.008 (2012).

Acknowledgements

We thank Damien Hudson (MCRI) and Craig Smith (MCRI) for the DT40 and DF-1 cells respectively, Marguerite Evans-Galea (MCRI) for the mouse brain and Yoshiko Takahashi (Kyoto, Japan) for Tol2 and transposase plasmids. We thank Matthew Burton and Paul Lau (Flow Cytometry-MCRI), Paul Kalitsis (Chromosomal Research-MCRI), Hwee Ong (Genetic Health Research-MCRI) and Alex Combes (Kidney Development, Disease and Regeneration) for their technical advice and support. The mCherry monoclonal antibody (3A11) was developed and supplied by the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242. This research was supported by NHMRC grant 1069757 and MCRI. HSCR-related constructs were contributed to by Foundation for Children 2014–211. We acknowledge the Victorian Government's Operational Infrastructure Support Program to MCRI. K.D.A.-B. holds an IPRS and APA(Int) PhD Scholarship through the Department of Paediatrics, University of Melbourne.

Author Contributions

K.D.A.-B. designed and performed the *in vitro* experiments. D.Z. and K.D.A.-B. performed and harvested the *in vivo* electroporation experiments. K.D.A.-B. and D.F.N. wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Abu-Bonsrah, K. D. *et al.* CRISPR/Cas9 Targets Chicken Embryonic Somatic Cells *In Vitro* and *In Vivo* and generates Phenotypic Abnormalities. *Sci. Rep.* **6**, 34524; doi: 10.1038/srep34524 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016